BACKGROUND The fixed drug eruption is a common adverse drug reaction. Clear identification of the culprit drug is not always possible in the clinical setting, and oral rechallenge may induce new lesions or severe reactions. OBJECTIVES The main purpose of this study was to evaluate the diagnostic value of patch testing in establishing an aetiological diagnosis in fixed drug eruptions. METHOD...

Five cases of balanitis due to fixed eruption after tetracycline therapy were reported by Csonka, Rosedale, and Walkden (1971) and since then a severe recurrent balanitic reaction has been observed in one patient after taking single doses of 'Mandrax' (diphenhydramine-methaqualone). No similar case appears to have been published. Case report An unmarried Caucasian male student, aged 20, attende...

Background Adverse reactions to drugs, Fixed Erythema (FE), correspond to 16-21% of all skin eruptions. This disease results in the development of one or more erythematous annular or oval, plaques as a result of systemic exposure to a drug. On reexposure relapse occurs in the same place, although new lesions may arise simultaneously in other areas. Any drug can cause FE. The physiopathology inv...

TNPM presents as subcorneal or intraepidermal pustules composed mainly of neutrophils; this finding helps to differentiate TNPM from NTE, in which there is a predominance of eosinophils. In conclusion, we must be aware that TNPM is a benign condition with no systemic manifestations and it does not require treatment. This entity can be confused with serious infections, and patients with TNPM may...

FDE: fixed drug eruption INTRODUCTION Mycophenolate is a reversible inhibitor of inosine monophosphate dehydrogenase, which plays an important role in the production of DNA. This drug is commonly used in several autoimmune and inflammatory conditions, including connective tissue diseases, immunobullous disease, and atopic dermatitis, and in the setting of organ transplantation. Mycophenolate is...